Targeted therapy of psoriasis: inhibition of the IL-23 signaling pathway - evidence from clinical studies and real practice
The article presents the results of clinical studies of the efficacy and safety of the use of a new drug of genetically engineered biological therapy guselkumab. Guselkumab is the first representative of the interleukin-23 (IL-23) inhibitor class and has a number of advantages over existing therapy....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology,
2020-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |